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INTRODUCTION 
 
Patients with diabetes have a 2-4 fold increase in risk of CAD. 
Better implementation of therapies that reduce cardiovascular risk in 
diabetic patients will require moving beyond the traditional primary focus 
on glycaemic control. A working knowledge of the effects of diabetes 
mellitus on the heart & blood vessels will aid physicians caring for these 
patients. In general population women experience relative protection 
from myocardial infarction and usually develop CAD approximately 10 
years later than men. However diabetes blunts the cardiovascular benefit 
of female gender. 
 
 In the first national health & nutrition examination survey 
(NHANES) & the NHANES epidemiologic follow up survey conducted 
10 years apart, age adjusted mortality decreased in non-diabetic men & 
women, less so in diabetic men, but increased by 23% in diabetic women. 
In the Gruppo  Italino per 10 studio della sopravvivenza bell Intarto 
miocardio – 2 ( GISSI – 2 ) study of thrombolytic therapy in patients with 
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myocardial infarction, diabetes increased the rate of death in men by 40% 
and women by 90%. 
 
 In the Finnish contribution to the WHO MONICA project (WHO 
Multinational Monitoring of Trends and Determinate of cardiovascular 
Disease) 1 year mortality was 38% higher for diabetic men & 86% higher 
for diabetic women. Silent myocardial ischemia which is common in 
diabetic patients can be detected by Treadmill test. Though it is said that 
treadmill false positivity is higher in females, various studies like  
Guiteras (1972 ), Linhart ( 1974 ), Sketeh (1975), Barolsky ( 1979 ), 
Weiner ( 1979 ), Ilsely ( 1982 ), Hung ( 1984 ), Hlatky (1984 ), Melin ( 
1985 ), Robert ( 1991 ), Chae ( 1993 ), Williams ( 1994 ), Marwiek ( 
1995 ), Morise ( 1995 ), shows the average sensitivity in women is 67% 
and specificity is 67.7%. So in developing nations like India, still tread 
mill test which is cost effective can be used as a investigation modality 
for diagnosing CAD in high risk population like diabetic women.  
 
 Diabetic Autonomic neuropathy is the most common and 
troublesome complication of type 2 Diabetes mellitus. Cardiovascular 
Autonomic neuropathy is a common form of Autonomic neuropathy 
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causing abnormalities in heart rate control, central and peripheral 
vascular dynamics. Cardiac autonomic neuropathy has been linked to 
postural hypotension, exercise tolerance, enhanced intra operative 
cardiovascular lability, increased incidence of asymptomatic ischemia, 
myocardial infarction and decreased likelihood of survival after 
myocardial infarction. Hypothesis concerning the multiple etiologies of 
diabetic neuropathy include metabolic insult to nerve fibers, 
neurovascular insufficiency, autoimmune damage and neuro-humoral 
growth factor deficiency. Cardiac autonomic neuropathy which is 
considered to be a cause for asymptomatic CAD in diabetics is tested by 
history and simple bedside tests. Its presence has been correlated with the 
silent myocardial ischemia. 
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AIM OF THE STUDY 
 
 
 
1. To study the prevalence of asymptomatic ischemic heart disease 
in diabetic women by exercise stress test. 
 
2. To correlate the presence of cardiac autonomic neuropathy with 
the asymptomatic ischemic heart disease 
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REVIEW OF LITERATURE 
 
Diabetes mellitus has become a major threat to human health. 
Diabetes mellitus is a strong risk factor for the CAD. Eighty percent of 
the all deaths among diabetic patients are due to atherosclerosis, 
compared with about 30% among non-diabetes. 
Diabetes accelerates the natural course of atherosclerosis in all 
groups of patients and involves a greater number of coronary vessels with 
more diffuse atherosclerotic lesions. There is two fold to four fold 
increase in the relative risk ratio of cardiovascular disease in Type 2 
diabetes mellitus compared to general population.1 
 
Diabetes in female population 
Diabetes is associated with a greater incremental risk in women, 
completely eliminating the female advantage. The American Heart 
Association awarded double weight to diabetes in women when 
calculating IHD risk. More than in men, diabetes dramatically increases 
the mortality of myocardial infarction in women. T2 DM is associated 
with obesity, SHT, atherogenic dyslipidemia and insulin resistance all of 
which have been associated with higher CHD risk. 1 
  6 
More so than is men, obesity and body fat distribution appears to be 
independent CAD risk factors in women. Diabetes is also linked with 
endothelial dysfunction and a variety of platelet abnormalities. 1 
Although equally likely to have effort angina, women with CHD 
are more likely than men to experience atypical symptoms such as pain at 
rest, during sleep (or) with mental stress. These differences make a 
gender based approach essential in the recognition and assessment of 
acute and chronic ischemic syndromes. Further non-coronary chest pain 
syndromes are more common in women, further complicating clinical 
assessment of chest pain in females. 1 
An overwhelming majority of women and unaware of their 
cardiovascular risk and physicians do little to educate them. Improvement 
in prevention of CAD in women requires earlier awareness and 
identification of risk. Early identification of glucose intolerance, 
abdominal adiposity and metabolic syndrome, with aggressive behavior 
modification and immediate weight loss is increasingly recognized as 
important. 1 
The average lipid profile in women is affected by normal status 
and changes throughout life. Young women have lower LDL levels and 
high HDL levels. As women age increases, LDL cholesterol increases, 
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HDL decreases and the risk of IHD increases. Associated systemic 
hypertension, smoking, post-menopausal state, obesity, dietary habits and 
physical inactivity add to the coronary atherosclerotic process. 1 
 
Coronary atherosclerosis in females: 
Estrogen protects premenopausal women from atherosclerosis by 
producing favorable lipid profile. The differences between men and 
women in atherosclerosis are not limited to gonodal hormones. Research 
has shown some fundamental variation in the underlying mechanisms of 
diseases. 1 
A Japanese study assayed a large population of myocardial infarction 
patients for the presence of 71 single nucleotide polymorphisms in 
candidates’ gene known to be relevant to the pathophysiology of 
atherosclerosis. Two were found to be significantly more prevalent in 
men - connexin 37 and P22 Phix and two different genes were relevant in 
women plasminogen activator inhibitor-I (PAI-I) and Snomelzia-1 
suggesting that the genetic basis underlying among heart disease varies 
by gender. 1 
Such genetic differences are manifest in the physiology of 
atherosclerosis, including plaque components (More cellular and fibrous 
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tissue in women), endothelial function (estrogen induced coronary 
vasodilatation) and homeostasis (higher fibrinogen factor VII levels in 
women). 1 
Although coronary thrombosis is overwhelmingly the most 
common cause of M.I in both genders, women are twice as likely to have 
plaque erosion (37% in women versus 18% is men). 1 
 
Non-invasive diagnostic testing in females: 
The general principles underlying non-invasive diagnostic testing 
do not differ in men and women. Resting ECG reveals a higher 
prevalence of repolarisation (ST-T) wave abnormalities in women with 
suspected CAD than in men (32% versus 23%).1 
 
Treadmill Test: 
Treadmill exercise testing is associated with a higher false positive 
rate and a lower false negative rate than in men (12% versus 40%) 
suggesting that routine testing reliably excludes the presence of CHD is 
women with negative tests. Variables that may alter test accuracy are 
resting ST & T wave abnormalities, peak exercise heart rate, number of 
diseased vessels, age, drug use (digitalis, diazepam) hyperventilation, 
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conduction abnormalities, LVH, MVPS, vasospasm and hormonal 
influences. 1 
In American College of Cardiology/American Heart Association 
guidelines for exercise testing in asymptomatic persons without known 
coronary artery disease, Class IIa indication is diabetic patients who plan 
to start vigorous exercise. 1 
The treadmill protocol should be consistent, with the patient’s 
physical capacity and the purpose of the test. In healthy individuals the 
standard “Bruce” protocol is popular, and large diagnostic and prognostic 
data base has been published using this protocol. 1 
The Bruce multistage maximal treadmill protocol has 3 min 
periods to allow achievement of a steady state before workload is 
increased. In older individuals (or) those whose exercise capacity is 
limited by cardiac disease, the protocol can be modified by two 3 minutes 
warming up stages at 1.7 miles per hour and with 0 percent grade and 
1.7Mph and 5% grade. 1 
 
Exercise physiology during treadmill test: 
Cardiac output increases 4-6 folds above basal levels during 
strenuous exertion in the upright position, depending on genetic 
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environment and level of training. The maximum heart rate can be 
estimated from the formula. 1 
                    MHR = 220 - age in years (with standard deviation of 12 
beats/min). 
The age predicted maximum heart rate is useful measurement for safety 
reasons. 
In post exercise phase, hemodynamics returns to baselines within 
minutes of termination of exercise. Vagal reactivation is an important 
cardiac deceleration mechanism after exercise and the acceleration is well 
in trained athletes but blunted in patients with chronic heart failure. 1 
The work done during the treadmill test is expressed in metabolic 
equivalents (MET) which refer to unit of oxygen uptake in a sitting, 
resting person. One MET is equivalent to 3.5ml O2/kg/min of body wt. 1 
Measured VO2 in Ml O2/min/kg determines number of   
  ml O2/Kg/min 
 
MET’s associated with activity 
Work activities can be calculated in multiples of METS. The 
measurements obtained with cardiopulmonary exercise testing are useful 
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in understanding an individual patients response to exercise and can be 
useful in the diagnostic evaluation of a patient with dyspnea. 1 
 
Types of ST Segment displacement in treadmill: 
In normal persons the PR, QRS and QT intervals shorten as heart 
rate increases - ‘P’ amplitude increases and the PR segment becomes 
progressively more down slopping in the inferior leads. 1 
 
‘J’ (Junctional) point depression is a normal finding during 
exercise. In patients with myocardial ischemia, however the ST segment 
usually becomes more horizontal as the severity of the ischemic response 
worsens. With progressive exercise the depth of the ST segment 
depression may increase, involving more ECG leads and the patient may 
develop angina. 1 
 
In the immediate post recovery part the ST segment, displacement 
may persist with down slopping ST segments and ‘T’ wave inversion, 
gradually returning to baseline after 5-10 min. In about 10% of patients 
the ischemic response may appear only in the recovery phase. 1 
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The eight different ECG patterns seen during exercise testing. 1 
1. The Normal and rapid upsloping ST segment responses are normal 
responses to exercise  
2. J Point depression with rapid upsloping ST segments is a common 
response in an older, apparently healthy population. 
3. Minor ST depression can occur occasionally at sub maximal 
workloads in patients with coronary disease; in this illustration, the 
ST segment is depressed 0.09mV (0.9mm) 80 msec after the J 
point. 
4. The slow upsloping ST segment pattern often demonstrates an 
ischemic response in patients with known coronary disease or 
those with a high pretest clinical risk of coronary disease. Criteria 
for slow upsloping ST segment depression include J point and ST 
80 depression of 0.15mV or more and ST segment slope of more 
than 1.0mV/sec. 
5. Classic criteria for myocardial ischemia include horizontal ST 
segment depression observed when both the J point and ST 80 
depression are 0.1 mV or more and ST segment slope is within the 
range of 1.0mV/sec. 
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6. Downsloping ST segment depression occurs when the J point and 
ST 80 depression are 0.1mV and ST segment slope is -1.0mV/sec. 
7. ST segment elevation in a non-Q wave noninfarct lead occurs 
when the J point and ST 60 are 1.0mV or greater and represents a 
severe ischemic response. 
8. ST segment elevation in an infarct territory (Q wave lead) indicates 
a severe wall motion abnormality and in most cases is not 
considered an ischemic response. 
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Non coronary Causes of ST Segment Depression1 
 
1.Severe aortic stenosis 9. Glucose Load 
 
2. Severe hypertension 10. Left ventricular hypertrophy 
 
3. Cardiomyopathy 11. Hyperventilation  
 
4. Anemia 12. Mitral valve prolapse 
 
5. Hypokalemia 13. Intraventricular condution disturbance 
 
6. Severe hypoxia 14. Preexcitation syndrome 
 
7. Digitalis use 
15. Severe volume overload (aortic, mitral 
regurgitation) 
 
8.Sudden excessive 
exercise 
16. Supraventricular tachyarrhythmias 
 
 
 
 
 Exercise Parameters Associated with an Adverse Prognosis and 
Multivessel Coronary Artery Disease. 1 
 
 
1.Duration of Symptom-limiting exercise <5METs 
 
 
2.Failure to increase systolic blood pressure > 120mm Hg, or a sustained 
decrease > 10mm Hg, or below rest levels, during progressive execise. 
 
 
3.ST segment depression > 2mm, downsloping ST segment, starting at 
<5 METs, involving > 5 min into recovery. 
 
 
4.Exercise-induced ST segment elevation (a V excluded) 
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5.Angina pectoris at low exercise workloads 
 
 
6.Reproducible sustained (>30sec) or symptomatic ventricular 
tachycardia 
 
 
7.Acute systemic illness (pulmonary embolism, aortic dissection)s 
 
 
Measurement of ST segment displacement: 
For purpose of interpretation, the PQ junction is usually chosen as 
the iso electric point. The TP segment represents a true iso electric point 
but is an impractical choice for most routine clinical measurements. The 
development of 0.1 mV (or) greater of ‘J’ point depression measurement 
from the PQ junction with a relatively flat ST segment slope (e.g.) <0.7 
to 1MV/sec), depressed 0.10 MV (or) more 80 m.sec after the ‘J’ point 
(ST 80) in three consecutive beats with a stable baseline is considered to 
be an abnormal response. 1 
When the ST 80 measurement is difficult to determine at rapid 
heart rate (>130 beats/min) the, ST 60 measurement should be used. The 
ST segment at rest may occasionally be depressed. When this occurring 
the ‘J’ point and ST 60 (or) ST 80 measurements should be depressed an 
additional 0.1 MV (or) greater to be considered abnormal. 1 
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When the degree of resting St depression is 0.1 MV (or) greater, 
the exercise ECG becomes less specific and myocardial imaging 
modalities should be considered. 1 
Exercise induced ST segment depression does not localize the site 
of myocardial ischemia nor does it provide a clue about which coronary 
artery involved. But exercise induced ST segment elevation is relatively 
specific for the territory of myocardial ischemia and coronary artery 
involved. 1 
Mechanism of ST segment depression 
Dynamic changes in coronary artery at the site of an 
atherosclerotic plaque may result in diminished coronary flow during 
static (or) dynamic exercise, instead of the expected that normally occur 
from coronary vasodilatation in a normal vessel; that is perfusion present 
distal to the stenotic plaque actually falls as during exercise, resulting in 
reduced subendocardial blood flow. Thus regional left ventricular 
myocardial ischemia may result not only from an increase in myocardial 
O2 demand during exercise but also from a limitation of coronary flow as 
a result of coronary vasoconstriction (or) inability of vessels to 
sufficiently vasodilate at (or) near the site of an atherosclerotic plaque. 1 
  18 
In normal persons, the action potential duration of the endocardial 
region is longer than that of the epicardial region and ventricular 
repolarisation is from epicardium to endocardium. The action potential 
duration is shortened in the presence of myocardial ischemia and 
electrical gradients are created, resulting in ST segment depression (or) 
elevation depending on the surface ECG leads. At the molecular level, 
activation of sarcolemmal ATP - sensitive potassium channels by 
ischemic ATP depletion may play a role. 1 
 
Non electrocardiographic observation in treadmill 
Blood Pressure 
The normal exercise response is to increase systolic BP 
progressively with increasing work loads to a peak response ranging from 
160-200 mmHg with the higher range of the scale in older patients with 
less compliant vascular system. In asymptomatic normotensive 
individuals an exaggerated exercise systolic and diastolic BP response 
during exercise (or) exaggerated peak systolic BP to 214 mmHg (or) 
greater (or) an elevated systolic (or) diastolic BP at the 3rd minute of 
recovery is associated with significant increased long term risk of 
hypertension. 1 
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Cardiac autonomic neuropathy (CAN) 
CAN probably contribute to the poor prognosis of CHD and CHF 
in diabetes. The majority of patients with CAN come to clinical attention 
with complaints of postural hypotension, resting tachycardia, exercise 
intolerance (or) prior myocardial ischemia (or) infarction. The risk for 
CAN depends on the duration of diabetes and the degree of glycaemic 
control and leads to parallel the development of other end organ disease 
related to diabetes such as retinopathy, nephropathy and vasculopathy. 
Symptoms and signs of CAN often occur relatively late in the natural 
history of this complication. 1 
 
Simple bed side tests for cardiac autonomic neuropathy diagnosis: 2 
 Normal Abnormal 
Heart-rate variation during deep 
breathing  
(Maximum-minimum (bpm) 
>15 <10 
 
Heart-rate increase on standing 
(15s after standing (bpm)) 
30th beat:15th beat ratio (RR interval) 
 
 
>15 
>1.04 
 
 
<12 
<1.00 
Heart-rate change during Valsava 
Maximum: minimum ratio >1.21 <1.20 
Postural fall in systolic BP 
2 min after standing (mmHg) <10 >20 
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Prevalence of Cardiac autonomic neuropathy (CAN) 1 
The reported prevalence of CAN varies with the population studied 
and methods used. Regarding of these variations CAN appears to be 
common in diabetes. A summary of 15 reports on CAN suggests that the 
prevalence  is in between 2.6 and 90% in diabetic population. The 
average incidence is about 30%. 
 
 
Pathology of Autonomic neuropathy in Diabetes: 7 
Pathologic changes in the autonomic nervous syndrome were 
studied postmortem in many diabetic cases. All had clinical evidence of 
peripheral sensory motor neuropathy and developed disturbances of 
autonomic function that included postural hypotension, diarrhea, bladder 
dysfunction and signs of cardiac denervation. In celiac and other 
sympathetic ganglia there were many distended (Giant) or vacuolated 
nervous as well as enlarged club shaped neural processes. The vagus 
nerve and sympathetic trunks showed severe loss of myelinated fibers. 7 
There were inflammatory changes in autonomic ganglia in all cases 
and in (or) around bundles of unmyelinated nerve fibers in many. These 
findings suggest that there may be several different pathogenetic 
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mechanisms involved in the development of autonomic neuropathy in 
diabetes. 7 
Diabetic patients have a high rate of coronary heart disease, which 
may be asymptomatic owing to autonomic neuropathy. Silent ischemia is 
significantly more frequent in patients with autonomic neuropathy than in 
those without autonomic neuropathy (38% versus 5%).4 
It is clear however that a reduced appreciation of ischemic pain can 
impair timely recognition of myocardial ischemia (or) infarction and 
there by delay appropriate therapy. 4 
In non-diabetic patients, acute myocardial infarction has a 
circadian variation with a significant morning peak. The characteristic 
diurnal variation in the occurrence of myocardial infarction is altered in 
diabetic patients with a lower morning peak and higher percentage of 
infarction during evening hours. The blunted morning surge of incidence 
of myocardial infarction results from altered sympatho-vagal balance in 
patients with cardiac autonomic neuropathy. Mortality rates after a 
myocardial infarction are also higher for diabetic patients than for non-
diabetic patients. This may be due to autonomic insufficiency, increasing 
the tendency for development of ventricular arrhythmia and 
cardiovascular events after infarction.4 
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Autonomic manifestations 
Abnormal autonomic function tests are often found in patients with 
clinical features of sensory neuropathy, and almost any aspect of 
autonomic function can be affected. However, symptoms of autonomic 
neuropathy are unusual and are commonest in patients with poorly 
controlled type I diabetes. In all of the autonomic syndromes described 
below, symptoms may be chronic or strikingly intermittent. 2 
Most longitudinal studies point to a common sequence of 
autonomic involvement in patients with diabetic autonomic neuropathy. 
In the cardiovascular system, the earliest abnormality detected by 
systematic and sensitive testing is a decrease in heart- rate variability 
during deep breathing, followed by alterations in the heart rate on 
standing and then the Valsalva maneuver. Postural hypotension is a 
relatively late event. This progression suggests that parasympathetic 
(vagal) fibers are damaged first, followed by the sympathetic outflow. 
Abnormal autonomic function tests are much more common than 
significant autonomic symptoms. 2 
Symptomatic, but not asymptomatic, autonomic neuropathy has 
been associated with a poor prognosis. But there is dispute as to whether 
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this is related to the neuropathy itself or to coexistent macrovascular 
disease or other complications. 2 
 
Abnormal sweating 
This is one of the commonest, but frequently neglected, symptoms 
of diabetic autonomic neuropathy. Gustatory sweating, precipitated by 
eating cheese and other foods, is characteristic. Sweating is often profuse 
over the face and sometimes upper chest, corresponding to the area 
supplied by the superior cervical ganglion. Some patients find this 
socially debilitating. 
Other abnormalities of sweating include the dry neuropathic foot, which 
allows cracking of the skin and the entry of infection, and episodic 
nocturnal sweating that cannot be attributed to hypoglycaemia. 2 
 
Cardiovascular changes 
These include abnormalities of the cardiovascular reflexes related 
to changes in posture and respiration, with severe postural hypotension in 
extreme cases. 2 
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Postural hypotension 
This is due to the impairment of the increase in cardiac output and 
of the sympathetically mediated vasoconstrictor response in the lower 
limbs, which normally follow standing upright. In diabetic neuropathy, 
this is a common manifestation of sympathetic denervation. It can be 
exacerbated by administration of insulin (which acts as a vasodilator at 
pharmacological concentrations) and of diuretics, antihypertensives and 
tricyclic antidepressants (which also have vasodilator activity). On 
standing, blood pressure is normally maintained, may rise slightly or may 
fall, but the systolic drop does not usually exceed 10 mmHg; a significant 
drop is generally taken as > 20 mmHg, although the magnitude of the 
systolic fall on standing does not correlate tightly with symptoms of 
dizziness. 2 
Postural hypotension is often worse on getting out of bed in the 
morning, but often varies substantially with time. The diagnosis is made 
simply by measuring the blood pressure with the patient lying and then 
standing for up to 2 min (some patients show a delayed fall).2 
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Athero thrombotic disease 
Atheroma develops earlier and faster in diabetes, leading to 
widespread lesions throughout the arterial tree, including the smaller 
arteries. Thickening of the intima is an early change. Hyaline 
degeneration and thickening of the muscular media may contribute to 
hypertension and often undergoes calcification (medial sclerosis). An 
important functional abnormality is impaired arterial relaxation, due to 
failure of the endothelium to produce nitric oxide (NO), a potent 
vasodilator. Procoagulant changes on the endothelial surface promote 
adhesion of macrophages (the precursors of foam cells of the 
atheromatous plaque) and platelets, favoring thrombosis. Platelet-rich 
thrombus in the coronary arteries is unstable and likely to rupture, 
causing acute coronary occlusion. 2 
Atherogenic risk factors like hyperglycemia, hypertension, 
dyslipidemia and central obesity cluster together with insulin resistance 
in the ‘metabolic’ syndrome (syndrome X), which is strongly associated 
with accelerated atheroma formation and cardiovascular disease. The 
presence of diabetes amplifies the effect of other coexisting risk factors. 
Disorders of coagulation and fibrinolysis are also associated with 
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syndrome X and probably contribute to atherothrombotic disease. 
Clustering of these factors is unexplained. 2 
Cardiovascular risk rises as blood glucose increases above 
subdiabetic levels. The relationship may be J-shaped. In diabetic people, 
tight glycaemic control has not yet been shown to reduce macrovascular 
events, except of metformin treatment, which significantly decreased 
fatal myocardial infarction rate in type 2 diabetic patients. Other actions 
of metformin (reducing pressure and obesity) may be responsible. 2 
Hyperglycemia leads to advanced glycation end-products (AGE) 
formation in the arterial wall, damaging structural proteins and generating 
toxic reactive oxygen species. Sequelae include increased endothelial 
permeability, impaired NO-mediated vasorelaxation, upregulation of 
procoagulant and adhesion proteins on the endothelium, and attraction of 
macrophages that form foam cells. AGEs interact with specific receptors 
(RAGEs) on endothelial and other cells to cause specific effects. Genetic 
polymorphisms of the RAGE gene may modulate production of 
inflammatory mediators in arteries. Insulin stimulates vascular smooth 
muscle cell proliferation and production of the fibrinolysis inhibitor, 
plasminogen activator inhibitor (PAI). High insulin levels in insulin 
resistant states may therefore be atherogenic. Other commonly associated 
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risk factors are hypertension (30-45% of diabetic people), dyslipidemia 
(typically raised low density lipoproteins, dominated by highly 
atherogenic small dense low-density lipoprotein, low high-density 
lipoproteins, raised triglycerides) and obesity, an independent risk factor.2 
 
Clinical syndromes and management 
Myocardial ischemia may present atypically or without pain, and 
‘silent’ ischemia carries a worse prognosis than in non-diabetic people. 
Vascular disease in the legs and cerebral circulation commonly coexist 
and are two to three times more frequent than in the general population. 
Early and extensive investigation (including invasive test such as 
coronary angiography) may therefore be needed in patients with few 
symptoms. 2 
Primary preventative measures includes weight loss if obese, regular 
physical activity and smoking cessation; optimizing glycaemic control, 
using metformin in obese type 2 patients; correcting dyslipidemia and 
hypertension; and aspirin (75mg/day). Target cholesterol concentration is 
<4.8 mmol/L, and blood pressure should be <135/85 mmHg. 2 
Beta blockers and angiotensin-converting enzyme (ACE) inhibitors 
are useful in treating angina and hypertension and also have cardio-
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protective effects in diabetic patients. ACE inhibitors also slow the 
progression of nephropathy, and some calcium-channel antagonists 
decrease the risk of infarction in diabetic people. Heart failure is treated 
conventionally with ACE inhibitors and diuretics; certain beta blockers 
(e.g. carvedilol) may also be useful. 2 
Unstable angina carries a 50% higher risk of progression to 
myocardial infarction than in non-diabetic subjects, and requires 
intensive treatment with low molecular-weight heparin and a beta 
blocker; addition of either clopidogrel or a platelet glycoprotein IIb/IIIa 
inhibitor (e.g. tirofiban), to block platelet aggregation, further reduces 
risk of infarction or death. Urgent coronary revascularization is indicated 
if medical measures fail. 2 
Acute myocardial infarction should be treated with immediate 
thrombolysis (even in the presence of retinopathy), aspirin and a 
cardioselective beta-blocker. An ACE inhibitor should be given early 
unless contraindicated. Blood glucose should be tightly controlled in all 
diabetic patients, according to the Diabetes Mellitus Insulin Glucose 
Infusion in Acute Myocardial Infarction (DIGAMI) protocol, 
insulin/glucose solution infused intravenously to maintain levels of 7-11 
mmol/L for at least 24h, followed by intensive subcutaneous insulin 
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treatment for at least 3 months. Insulin given in this way may reduce 
myocardial damage from non-esterified fatty acids and block excessive 
neuroendocrine activation. 2 
Coronary revascularization relieves symptoms as effectively in 
diabetic as in non-diabetic people, although long-term survival is lower. 
Percutaneous transluminal coronary angioplasty (PTCA) with stenting 
(and probably a platelet inhibitor) is preferred for accessible lesions in 
larger vessels. Coronary artery bypass grafting (CABG) is generally 
reserved for difficult or multiple occlusions and for re-stenosis after 
angioplasty.2 
 
Dyslipidemia in T2 D M  
Lipid metabolism is commonly deranged by the diabetes mellitus, 
often with additional contributions from coexistent renal or hepatic 
disorders. These lipid alterations play an important role in the 
development of atherosclerosis, and contribute to the instability of 
atheromatous plaques. Gross hypercholesterolemia is not a feature of 
diabetic dyslipidemia, but at any given level of cholesterol, a diabetic 
subject has two to three times the cardiovascular risk of non- diabetic. 2 
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Lipid abnormalities associated with type I diabetes are largely 
related to the level of glycaemic control. Hyperglycemia is associated 
with raised low-density lipoprotein (LDL) cholesterol and triglyceride 
concentrations and low HDL-cholesterol, abnormalities which are 
reversed by normalizing glycaemia. 2 
The pattern of dyslipidemia in type 2 diabetes is that 
characteristically seen in the insulin-resistant states and the metabolic 
syndrome. Low HDL and raised triglyceride concentrations are 
accompanied by normal LDL-cholesterol levels, although this is likely to 
be dominated by highly atherogenic small dense LDL particles. Non-
diabetic but insulin resistant first degree relatives of type 2 diabetic 
subjects share this atherogenic profile, suggesting that it precedes the 
development of clinical diabetes. 2 
Systemic hypertension 
Hypertension commonly coexists with type 1 and type 2 diabetes 
and is particularly associated with diabetic nephropathy. In its own right, 
it is a major risk factor for both myocardial infarction and stroke. In the 
UKPDS, 32°/o of type 2 diabetic males and 45°/o of females with no 
clinical evidence of atheromatous disease were hypertensive (according 
to the World Health Organization criteria of systolic pressure> 160 
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mmHg, and/or diastolic > 90 mmHg) or were taking antihypertensive 
drugs. In male subjects who already had coronary-artery disease, the 
prevalence of hypertension was even higher at 46%.2 
Hypertension is an important feature of the cluster of 
cardiovascular risk factors termed the metabolic syndrome. The links 
between these factors remain largely unexplained. The characteristic 
dyslipidemia of insulin resistance may contribute to hypertension, as 
small dense LDL particles are especially susceptible to oxidation, and 
oxidized LDL can suppress endothelial NO production and so promote 
vasoconstriction; hypertriglyceridemia also impairs endothelium-
dependent vasorelaxation. A role of dyslipidemia is supported by studies 
showing that fibrates used to treat hypercholesterolaemia also reduced the 
prevalence of hypertension by up to 25%.2 
Obesity 
Obesity predisposes to type 2 diabetes, and to hypertension, 
dyslipidaemia and ultimately atheroma - one of the major causes of 
premature death in the obese. Indeed, obesity is now recognized as a 
cardiovascular risk factor in its own right. 2 
Truncal or male-pattern obesity, with excess fat deposited both 
subcutaneously around the abdomen and within the visceral cavity is 
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particularly associated with type 2 diabetes and the other components of 
the metabolic syndrome. For unknown reasons, truncal obesity is 
associated with insulin resistance and proinflammatory responses that 
cause glucose intolerance and a highly atherogenic risk profile. Candidate 
mediators produced by adipose tissue that may contribute include NEFAs 
and cytokines such as TNF-alpha. Reduced levels of adiponectin, an 
insulin sensitizing protein whose secretion by adipose tissue is 
paradoxically decreased in obesity, may also contribute to both insulin 
resistance and atherogenesis. The thiazolidinediones ameliorate some of 
these adverse effects of adipose tissue (e.g. lowering NEFA levels), 
raising the prospect that these agents may reduce cardiovascular risk in 
type 2 diabetes. 2 
 
Haemostasis in diabetes 
Diabetes is associated with a variety of abnormalities in 
coagulation, fibrinolysis and platelet function. These include increases in 
specific procoagulant proteins - factor VIII , vWF, factorVII , factor X 
and fibrinogen together with potentially prothrombotic decreases in the 
coagulation inhibitors, protein and antithrombin III. Some of these 
disturbances differ quantitatively between type 1 and type 2 diabetes, and 
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some show particularly strong associations with atherothrombotic disease 
and with microvascular complications, especially nephropathy. 2 
 
Cardiovascular autonomic neuropathy and increased cardiovascular 
morbidity and mortality in diabetes mellitus possible mechanisms1 
 
1. Impaired angina recognition Silent ischemia and infarction. 
2. Decreased threshold for ischemia 
 Increased resting heart rate and blunted chronotropic response to 
exercise, 
 Impaired coronary vasomotor regulation. 
3. Prolonged QT interval 
    Increased lethal arrhythmias and sudden death (with or without 
myocardial ischemia) 
4. Abnormal diastolic and systolic function 
Contributes to diabetic cardiomyopathy. Increased cardiac mass 
Adversely affects the natural history of congestive heart failure 
5. Increased peri-operative risk  
Increased need for hemodynamic support 
Reduced hypoxia-induced respiratory drive . 
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6. Alteration of normal circadian variation of sympatho-vagal activity 
 Lack of normal nighttime decrease in blood pressure 
 Loss of night time protection against myocardial infarction 
7. Increased prevalence of other cardiovascular risk factors and other 
Complications  
Increased microvascular complication 
Increased rate of progression of glomerolopathy 
Increased prevalence of hypertension and dyslipidemias1 
 
PHARMACOLOGIC MANAGEMENT FOR CONTROL 
DIABETES3 
 
Sulfonylureas: 
 Sulfonylureas are the typical therapy for lean patients with type 2 
disabetes and are used in combinations with other agents in obese type 2 
patients. Sulfonylureas bind to a receptor on the beta cells and inhibit the 
sodium-adenosine triphosphate (Na-ATP) channel; an increase in 
intracellular calcium results in insulin exocytosis. 
 
 Some experts point to a possible risk of increased myocardial 
damage in patients with known CAD who use sulfonylureas at the time 
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of an ischemic event. Prevention of protective ischemic preconditioning 
of the heart by inhibition of the potassium (K)-ATP channel is the 
putative mechanism. The UKPDS data do not support this concern. The 
authors agree and use sulfonylureas in appropriate patients with CAD. 3 
 
Repaglinide: 
 
 This newer insulin secretagogue binds to a different receptor site 
than do the sulfonylureas on the K-ATP channel. The half-life of this 
agent is 3.7 h, which makes it effective for postprandial rather than 
preprandial hyperglycemia, for use in the elderly and for diabetic patients 
with chronic renal failure. 3 
 
Metformin: 
 
Metformin is a biguanide drug that has been in use in Europe for over 30 
years and was approved in the United States in 1995. The main mode of 
action of metformin is decreasing hepatic glucose output primarily by 
inhibiting gluconeogenesis, typically without hypoglycemia. 
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Metformin is effective alone or in combination with insulin, 
sufonylureas, and thiazolidinediones. The drug usually results in weight 
loss as a result of decreased appetite for up to 1 year after the inititation 
of therapy. 
 
Significant decrease in LDL cholesterol and triglycerides occur. The 
incidence of lactic acidosis with metformin is 9 per 100,000 person-
years. Contraindications to its use include an elevated creatinine level 
(>1.4 in women, <1.5 in men), congestive heart failure, severe pulmonary 
disease, or any hypoxic state. 3 
 
Thiazolidinediones: 
 Thiazolidinediones promote insulin-stimulated glucose transport in 
muscles and adipocytes through a mechanism of action involving 
actuating peroxisome proliferators activated receptor-gamma (PPAR-γ) 
ligands. Binding to the nuclear receptor promotes differentiation of 
adipocytes and increased expression of glucose 
transporter.Thiazolidinediones has been shown to be effective both as 
monotherapy and in combination with insulin, sulfonylureas, and 
metformin. 3  
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Endogenous C peptide is necessary for all the thiazolidinediones to 
be effective when used in combination with insulin. These agents can 
result in a reduction from two injections of insulin a day to one. 
Triglyceride levels can be lowered with troglitazone. There is a small 
increase in the plasma LDL concentration, along with a favorable 
increase in the ratio of buoyant LDL to the more antherogenic small 
dense LDL. The thiazolidinediones are associated with weight gain partly 
resulting from improvement in glycemic control. With troglitazone, 
monitoring of liver function should be done monthly for the first year and 
quarterly thereafter. 3 
Troglitazone has resulted in fulminate hepatic failure in about 1 in 
60,000 patients on the medication; this is felt to be an idiosyncratic 
reaction. Patients with a history of liver disease, possibly including 
hepatitis C (depending on severity), and those who ingest more than a 
moderate amount of alcohol should not be started on this agent. Because 
of the potential for liver disease, troglitazone has been removed from use 
by the FDA. 3 
 Two other drugs in this class were approved by the U.S. Food and 
Drug Administration (FDA) in mid-1999, and the data to date support 
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equal efficacy with less hepatotoxicity. No head – to- head studies of 
these agents are available. Monitoring of liver function tests with 
rosiglitazone and pioglitazone is recommended every 2 months for the 
first year and periodically thereafter, since it has not been determined that 
serious liver events with troglitazone are a class effect of the 
thiazolidinediones or are specific to troglitazone. 3 
Rosiglitazone monotherapy results in a decrease of Hb A1c of 0.8 
to 1.5 percent greater than that seen with placebo, with the greatest 
reduction seen when it was given in two divided doses. Combination 
studies of rosiglitazone with metformin for 26 weeks resulted in a 1.0 to 
1.2 percent placebo-adjusted decrease in HbA1c. Although rosiglitazone 
is currently approved for use as monotherapy and in combination therapy 
with metformin, it also is expected to be efficacious with sulfonylureas or 
insulin. Rosiglitazone has been reported to result in an increase in LDL 
and HDL cholesterol concentrations between 12 and 19 percent, with 
changes in serum triglycerides similar to those seen with placebo. 3 
Pioglitazone, the newest thiazolidinedione, has been approved for 
use as monotherapy and in combination with metformins, sulfonylureas, 
and insulin. In three randomized, double-blind placebo controlled trials 
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of 16to26 weeks duration, changes in HbAlc were 1.0 to 1.4 percent. 
Increases in  
alanine aminotransferase (ALT) occurred in 0.26 percent of treated 
patients, a result that was not different from that with placebo. Patients 
treated with pioglitazone showed a decrease in serum triglyceride (9.3 to 
9.6 percent), increases in HDL (12.2 to 19.1 percent), and increases in 
LDL (5.2 to 6.0 percent) with the 30-45-mg doses, respectively. 3 
 
Alpha-Glucosidase Inhibitors: 
Acarbose and miglitol work in the intestine to reversibly inhibit 
brush border alpha-glucosidases, resulting in a delay in carbohydrate 
absorption. Only about I percent of the drug is absorbed from the 
gastrointestinal tract. These drugs cause a 30 percent decrease in 
postprandial glucose in contrast to a 10 percent decrease in fasting 
glucose levels. They are adjuncts to other oral agents and rarely are 
potent enough to be used as mono therapy. 3 
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Insulin: 
 
 The natural history of type 2 diabetes is one of progressive beta-
cell failure. Therefore, after approximately 10 years of the use of oral 
hypoglycemic agents, insulin will be required in combination with oral 
agents as the sole therapy. Although endogenous hyperinsulinemia is 
clearly associated with atherogenesis, there is no compelling evidence of 
increased risk of cardiovascular disease or increased mortality from 
exogenous insulin therapy. 3 
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MATERIALS AND METHODS 
 
PLACE OF STUDY 
 Institute of internal medicine 
 Madras medical college & Government general hospital 
 Chennai 03 
 
INCLUSION CRITERIA 
1. Known diabetic women on treatment (OHA & insulin therapy) 
2. Diabetic women not on treatment for CAD 
3. Patients not on beta blockers 
4. Duration of diabetes within 10 years 
5. Echocardiography normal 
 
EXCLUSION CRITERIA 
1. Patients with peripheral vascular disease as evidenced by absent 
peripheral pulses 
2. Type 1 diabetes mellitus 
3. Known case of coronary artery disease 
4. Signs of left ventricular failure 
  42 
5. Uncontrolled systemic hypertension 
6. High risk unstable angina 
7. Age > 65 yrs 
8. Other absolute contraindications for exercise stress test 
 
 STUDY POPULATION 
 
 Of the 107 patients enrolled for the study who attended out patient 
clinic of institute of internal medicine, Government General Hospital, 30 
patients were selected for the treadmill test and presence of cardiac 
autonomic neuropathy in them was tested by history and simple bed side 
tests. Other 77 patients are excluded as per exclusion criteria. 
 These groups of patients were investigated in dept of cardiology 
Govt. Gen Hospital and other appropriate investigations are done in 
biochemistry lab attached to op department, Govt. Gen Hospital. 
Autonomic neuropathy testing by simple bet side test was done in op 
department using ECG monitor and BP apparatus for the same 30 
patients. 
 Tread mill test was performed for these 30 patients using standard 
Bruce protocol. 
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STUDY DESIGN 
The presence of Cardiac autonomic neuropathy was correlated 
with the associated asymptomatic ischemic heart disease. Asymptomatic 
ischemic heart disease patients are those who are positive for inducible 
ischemia in TMT but without having angina at rest.  
 
LAB METHODS 
 In the study population fasting plasma glucose was measured using 
glucose oxidase & pyruvate oxidase methods from over night fasting 
sample and results were read by calorimeter. With the same method 
postprandial blood sugar was measured 2 hrs after the breakfast. 
 
BODY MASS INDEX 
Body mass Index was calculated using the formula 
 BMI   =      Weight (in Kg) / Height in metre2  
 In the study population, Body mass index of <25, 25 to 30 and >30 
are divided into three groups. TMT positivity in these groups was 
analyzed.  
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CARDIAC AUTONOMIC NEUROPATHY 
Cardiac Autonomic neuropathy was tested by 
1. Heart rate response to deep breathing. 
  Deep breathing is defined as 6 breaths per minute with 5 seconds 
of inspiration & 5 seconds of expiration, the maximum and minimum 
heart rate is measured. 
 2. Heart rate increase15 sec after standing using E C G monitor 
3. Drop in systolic blood pressure 2 minutes after standing 
 Cardiac autonomic neuropathy is said to be positive when 
heart rate variation to deep breathing is less than 10, heart rate 
increase 15 seconds after standing is less than 12 and drop in systolic 
BP 2 minutes after standing is more than 20 mmHg.  
Though other tests like ratio of RR interval between 30 and 15 beat 
after standing and heart rate change during valsalva maneuver are 
available, due to simplicity, practical difficulty and patients acceptance 
these tests are omitted .In various international studies positivity of 2 
out of 5 bed side tests was taken as cardiac autonomic neuropathy 
positive. In our study positivity of 3 bed side tests are considered as 
positive for CAN. Apart from the tests cardiac autonomic imbalance was 
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also tested by detailed history. In the history symptoms suggestive of 
orthostatic intolerance8 like  
H/o light headedness  
          H/o weakness or tiredness 
H/o cognitive difficulty (thinking /concentrating) 
         H/o vertigo 
          H/o anxiety  
          H/o palpitations 
          H/o sweating abnormality 
          H/o diarrhea 
          H/o constipation 
Since cardiac autonomic neuropathy is usually associated with 
other features of autonomic neuropathy this questioner was useful in 
assessing the patients along with the bed side tests. 
 
TREAD MILL TEST: 
Techniques 
 1. The standard Bruce protocol was used since large diagnostic and 
prognostic data base has been published using this protocol. The Bruce 
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multistage maximal treadmill protocol has 3 minutes periods to allow 
achievement of steady state before work load is increased. 
2. Patients were instructed not to eat drink caffeinated beverages 
for 3 hours before testing and to wear comfortable shoes and loose fitting 
cloths.             
3. Unusual physical exertion was avoided before testing.  
4. Patients were advised about the risks and benefits of the 
procedure.     
5. A written informed consent form was obtained. 
6. Adequate skin preparation was done to obtain high quality 
recordings. 
7. The areas of electrode application are rubbed with an alcohol 
pad to remove oil & rubbed with free sand paper and a rough material to 
reduce to skin resistance to 5000 ohms.  
8. Cables connecting the electrodes and recorders were light 
flexible and properly shielded.  
9. Room temperature was adjusted between 64 and 72˚f (18 & 22˚ 
c) and humidity less than 60%. 
 10. Tread mill walking was demonstrated to the patients. 
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          11. The heart rate, blood Pressure and ECG were recorded at the 
end of each stage of exercise. Immediately before & immediately after 
stopping exercise, at the onset of an ischemic response and for each 
minute for at least 5-10 minutes in the recovery phase. 
          12. A minimum of three leads were display continuously on the 
monitor during the test. 
13. Patients were at the sitting position immediately after the 
exertion.       
14. The supine position was avoided because it increases end 
diastolic volume and has the potential to augment ST segment changes. 
TMT RESULTS INTERPRETATION 
Normal persons  
 In normal persons, PR, QRS and QT intervals shorten as the heart 
rate increases. P amplitude increases and PR segment becomes 
progressively more downsloping in the inferior leads. J point or 
junctional depression is the normal finding during exercise. 
 
Abnormal response 
 The development of 0.1 mV (1 mm) or greater of J point 
depression measured from the PQ junction with a relatively flat ST 
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segment slope, depressed 0.1 mV or more 80 m.sec after the J point (ST 
80) in 3 consecutive beats with a stable baseline is considered to be an 
abnormal response. When the ST 80 measurement is difficult, to 
determine at rapid heart rate (>130 beats/min), ST 60 measurement is 
used.    
In our study 
1. ST segment depression of > =1mm during exercise and early 
recovery period was considered to be TMT positive for 
inducible ischemia.  
2. Development of classical angina during the test is considered to 
be strongly positive response.  
Workload 
 Workdone during the exercise stress test is expressed in MET 
(Metabolic equivalents). 1 MET = 3.5 ml/O2/min/Kg of body 
weight. 
Exercise time  
 Exercise time is calculated in minutes. Each stage is consisted of 3 
minutes  
Hypertension 
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 Hypertensive response during treadmill was considered when 
systolic BP raised more than 214 mmHg. These types of patients 
are more prone to develop hypertension in the future.  
The TMT was terminated if the patient developed any of the 
following features. 
1. Drop in systolic blood pressure despite an increase in workload 
2. When accompanied by other evidence of ischemia 
3. Moderate to severe angina (grade ¾) 
4. Increasing nervous system symptoms (e.g., ataxia, dizziness or near-
syncope) 
5. Signs of poor perfusion (cyanosis or pallor) 
6. Technical difficulties in monitoring ECG or systolic blood pressure 
7. Subject’s desire to stop 
8. Sustained ventricular tachycardia 
9. ST elevation (≥1.0mm) in non infarct leads without diagnostic Q waves 
(other than V1 or aVL) 
10. Fatigue, shortness of breath, wheezing, leg cramps, or claudication 
11. Development of bundle branch block of intra ventricular conduction 
delay that cannot be distinguished from ventricular tachycardia 
12. Hypertensive response       
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STATISTICAL ANALYSIS 
 
 
Statistical analysis was carried for 30 subjects after categorizing 
each variable. Autonomic neuropathy bedside tests are performed for all 
the patients. Age, duration of diabetes, BMI, systemic hypertension, 
menopause and percentage of CAN positivity in TMT positive and 
negative group were analyzed. The significance of difference in mean 
between means were calculated using z test and difference in proportions 
using chi-square statistic. 
 
Statistical significance is taken when P < 0.05. Statistical analysis 
was carried out using standard formulae. Microsoft excel 2003 and SPSS 
(statistical package for social sciences) version 13.0 softwares were used 
for data entry and analysis.  
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                                        OBSERVATIONS 
 We included 30 diabetic women for the study and all of them 
underwent treadmill test. Treadmill test was done by standard Bruce 
protocol.  
 
Table.1 Prevalence of asymptomatic IHD in female diabetics 
Total number of patients in 
whom TMT was done 
 
TMT positive 
 
Percentage 
 
30 
 
9 
 
30% 
 
 
Table.2 Patient characteristics 
 
 
TMT Positive 
group 
TMT Negative 
group P value 
Number 9 19  
Age 49.78 ± 8.11 45.21 ± 7.66 0.16 
BMI 27.39 ± 3.91 27.01 ± 4.10 0.84 
Mean duration 
of diabetes 5.78 ± 3.31 4.32 ± 2.81 0.27 
% of autonomic 
neuropathy 
positivity 
77.78% 10.52% <0.001 
SHT 55.55% 42.1% 0.48 
Menopause 22.22% 15.78% 0.69 
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Table.3 TMT parameters in patients  
 TMT positive TMT negative P value 
Exercise time 5.51 ± 1.91 7.43 ± 2.19 0.016 
Workload in 
METs 8.81 ± 2.28 10.59 ± 2.71 0.06 
% Predicted 
maximum HR 91.5 ± 9.71 90.71 ± 10.14 0.12 
 
 
Table.4 CAN predictors in patients      
  
 TMT positive TMT negative P value 
HR variation to 
deep breathing 11.67 ± 7.45 20.16 ± 5.41 0.0027 
HR increase 15 
seconds after 
standing 
12.22 ± 3.90 16.47 ± 2.65 0.0026 
Drop in SBP 2 
min After 
standing 
20.67 ± 7.42 8.95 ± 6.01 <0.001 
 
                        In our study the study population is divided in to TMT 
positive and TMT negative group. They are matched for age, BMI, mean 
duration of diabetes, percentage of CAN positivity, systemic 
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hypertension and menopause. There is no statistical difference is noted 
between these two groups in age, BMI , mean duration of diabetes, 
systemic hypertension and menopause. In all these parameters compared 
between these two groups the ‘p’ value is more than 0.05 which is 
statistically insignificant .But for cardiac autonomic neuropathy between 
these two groups the ‘p’ value is <0.001.This value is statistically 
significant and it shows the strong association of cardiac autonomic 
neuropathy in the TMT positive group. 
TMT parameters like exercise duration in minutes,% of target heart 
rate and work done in METs are compared between TMT POSITIVE  
and TMT NEGATIVE groups. In this, exercise done in minutes between 
these two groups show statistically significant ‘p’ value (0.016). This 
shows the poor exercise capacity in the TMT positive groups.  
  While comparing both groups for heart rate  variation to deep 
breathing, heart rate increase 15 sec after standing  and drop in SBP 2 
min after standing , the ‘p’ values are 0.0027,0.0026 
and<0.001respectively. This shows the strong association of cardiac 
autonomic neuropathy in TMT POSITIVE group. 
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Important observations noted are 
 
1. There was strong association of cardiac autonomic neuropathy in the  
TMT positive group.  
 
2. Poor exercise capacity was noted in the TMT positive group. 
  
CHARTS 
 
 
Fig1. Age distribution 
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Fig.2 Age wise TMT positivity 
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Fig.3 TMT Positivity 
 
 
 
Fig.4 Duration of diabetes and TMT positivity 
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 Fig.5 TMT positivity in Hypertensives 
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Fig.6 TMT positivity in Post menopausal women 
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Fig.7 Obesity and TMT positivity 
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Fig.8 Cardiac Autonomic Neuropathy – prevalence in diabetes 
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Fig.9 TMT positivity in cardiac autonomic neuropathy patients 
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Fig.11 Prevalence of angina in CAN positive patients 
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DISCUSSION 
      
 
In our study the prevalence of asymptomatic ischemic heart 
disease is found to be 30%. In various other international studies the 
prevalence of asymptomatic IHD in diabetes varies between 10-77%. 
Indian studies done by Shah et al and Banerjee et al show the prevalence 
of 36% any 35% respectively. 
 
In one study conducted in Dept of cardiology, central railway head 
quarter hospital, Byculla, Bombay the prevalence of TMT positivity is 
38% and autonomic neuropathy in tread mill positive patients was 72.2%. 
In our study in which female diabetics are the target population the TMT 
positivity was slightly lower (30%). 
 
Cardiac autonomic neuropathy in TMT positive patients in our 
study is 77.78%. This almost matched the study done at (C.R.H.S.) 
Bombay. In the tread mill negative group the CAN positivity rate is 
22.22%.6 
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In various analysis the CAN prevalence in diabetic population 
varies from 5 to 90% with the average of 30%.1 In our study the 
prevalence of cardiac autonomic neuropathy is 30% which exactly 
matches the international studies. 
 
In our study cardiac autonomic neuropathy is positive in 7 out of 9 
TMT positive cases. This shows the strong relationship of the cardiac 
autonomic neuropathy with the silent myocardial ischemia. 
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CONCLUSION 
 
 
1. The prevalence of asymptomatic ischemic heart disease was higher 
in diabetic women when compared to non diabetics. About one 
third of diabetic women are having asymptomatic ischemic heart 
disease which can be detected by simple treadmill test. 
 
2. Prevalence of cardiac autonomic neuropathy was higher in 
treadmill positive patients who are otherwise asymptomatic. This 
shows that there is significant association between silent 
myocardial ischemia and cardiac autonomic neuropathy in diabetic 
population.  
 
3. Poor exercise capacity was noted in the TMT positive but 
otherwise asymptomatic diabetic women. 
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SCOPE FOR FUTURE STUDY 
 
 
1. In cardiac autonomic neuropathy positive diabetic patients, the 
incidence of ventricular arrhythmias are common. So this causes 
poor prognosis in cardiac autonomic neuropathy positive diabetics 
when they develop acute myocardial infarction. This aspect needs 
detailed analysis in future. 
 
2. In all our patients we noticed poor glycemic control. In future 
studies, reversibility of cardiac autonomic neuropathy with the 
tight glycemic control can be studied. This may be useful to the 
clinician treating the diabetic patients. 
 
3. Studies are also needed to check whether drugs used for the other 
diabetic microvascular complication can reverse the cardiac 
autonomic neuropathy. 
 
4. Since insulin therapy exacerbates postural hypotension the 
incidence of autonomic neuropathy in them needs separate detailed 
analysis. 
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HIGH RISK UNSTABLE ANGINA 
OTHER ABSOLUTE CONTRA INDICATION FOR EXERCISE 
TESTING 
AGE > 65 YEARS 
   
TREADMILL TEST 
 
CO EXISTING FACTORS 
SYSTEMIC HYPERTENSION 
MENOPAUSAL STATUS 
MAXIMUM INCIDENCE BETWEEN WHAT AGE 
DURATION OF DM WITH IHD 
OBESITY WITH IHD  
HYPERCHOLESTEROLEMIA WITH IHD 
CONTROL OF DIABETES 
  
S.No 
Name Age Ht Wt BMI BSA DURn ECG ECHO 
Exer 
time METS THR 
Max 
HR % 
1 Beena 42 155 65 27.06 1.64 3 n n 6.58 10.1 178 143 80.3 
2 Suseela 54 150 60 26.67 1.54 9 T↓ V3-V6 n 6.27 10.1 166 128 77.1 
3 Jayalaxmi 40 150 47 20.89 1.39 2 n n 9.09 13.5 180 155 86.1 
4 Chandrakala 54 150 50 22.22 1.43 6 n n 7.39 10.1 166 165 99.4 
5 Manjala devi 35 150 55 24.44 1.49 1 n n 12.27 17.3 185 160 86.5 
6 Gowri 45 150 55 24.44 1.49 5 n n 9.08 13.5 175 154 88.0 
7 Kala 49 155 60 24.97 1.58 7 n n 6.5 10.1 171 126 73.7 
8 Navaneetham 45 163 68 25.59 1.73 3 n n 6.17 10.1 175 154 88.0 
9 Saraswathi 32 158 65 26.04 1.66 1 n n 7.44 10.1 188 163 86.7 
10 Sarala 46 150 60 26.67 1.54 6 n n 8 10.1 174 188 108.0 
11 Padmavathy 37 150 62 27.56 1.56 2 n n 8.01 10.1 183 169 92.3 
12 Samundeshwari 55 150 65 28.89 1.6 7 n n 9.27 13.5 165 133 80.6 
13 Vijayakumari 47 155 70 29.14 1.69 4 n n 7.34 10.1 173 140 80.9 
14 Uma 45 155 70 29.14 1.69 5 n n 5.31 7.1 175 172 98.3 
15 Kasturi 40 145 75 35.67 1.66 1 T↓ V4-V6 n 9.05 13.5 180 184 102.2 
16 Janaki 52 150 50 22.22 1.43 8 n n 6.24 10.1 168 163 97.0 
17 Kamala 60 150 55 24.44 1.49 9 n n 8.03 10.1 160 160 100.0 
18 Jeyakumari 41 145 56 26.63 1.46 1 T↓ V1-V5 n 8.56 10.1 179 195 108.9 
19 Srikala 36 160 93 36.33 1.95 2 n n 1.39 4.7 184 147 79.9 
20 Rajalaxmi 55 150 60 26.67 1.54 9 n n 6 7.1 166 146 88.0 
21 Muthammal 45 160 80 31.25 1.83 3 n n 6.06 10.1 175 138 78.9 
22 Vijayalaxmi 49 150 50 22.22 1.43 5 n n 6.45 10.1 171 172 100.6 
23 Jayalaxmi 59 160 65 25.39 1.67 9 n n 7.24 10.1 161 157 97.5 
24 Surya 47 150 55 24.44 1.49 3 T↓ V1-V6 n 3.51 7.1 173 167 96.5 
25 Parvathi 55 160 65 25.39 1.67 9 n n 8.43 13.5 161 148 91.9 
26 Prabha 50 150 60 26.67 1.54 1 n n 4.32 7.1 170 157 92.4 
27 Usha rani 46 150 65 28.89 1.6 9 n n 7.49 10.1 174 181 104.0 
28 Beula 62 160 80 31.25 1.83 9 n n 4.52 7.1 158 133 84.2 
29 Poongavanam 35 155 65 27.06 1.64 2 T↓ V4-V6 n 4.38 7.1 185 136 73.5 
30 Mumtaz Begam 45 140 69 35.20 1.47 5 n n 3.21 7.1 175 145 82.9 
 
 
 
Master chart
  
S.No Name Age TMT result Auto NP Chest pain SHT Menopause 
HR 
variation 
to deep 
breathing 
HR 
increase 
15 sec 
after 
standing 
Fall in 
SBP 2 min 
after 
standingn 
CAN 
History 
1 Beena 42 inconclusive negative No No No 21 19 6 No 
2 Suseela 54 inconclusive negative Yes Yes No 25 17 8 No 
3 Jayalaxmi 40 negative negative No Yes No 25 18 8 No 
4 Chandrakala 54 negative negative No No No 22 18 6 No 
5 Manjala devi 35 negative negative No No No 23 17 8 No 
6 Gowri 45 negative negative No No No 23 17 6 No 
7 Kala 49 negative negative No Yes No 26 18 8 No 
8 Navaneetham 45 negative negative No Yes No 18 16 6 No 
9 Saraswathi 32 negative negative No No No 26 18 8 No 
10 Sarala 46 negative negative No No No 18 17 10 No 
11 Padmavathy 37 negative negative No No No 20 16 6 No 
12 Samundeshwari 55 negative negative No Yes Yes 24 19 8 No 
13 Vijayakumari 47 negative negative No No No 22 16 6 No 
14 Uma 45 negative negative No No No 23 18 8 No 
15 Kasturi 40 negative negative No No No 19 19 8 No 
16 Janaki 52 negative negative Yes Yes No 24 16 6 No 
17 Kamala 60 negative negative Yes No Yes 18 18 6 No 
18 Jeyakumari 41 negative negative Yes No No 21 17 6 No 
19 Srikala 36 negative negative Yes Yes No 17 16 6 No 
20 Rajalaxmi 55 negative positive No Yes Yes 6 9 30 Yes 
21 Muthammal 45 negative positive No Yes No 8 10 20 Yes 
22 Vijayalaxmi 49 positive negative Yes No No 27 19 8 No 
23 Jayalaxmi 59 positive negative Yes Yes Yes 22 19 8 No 
24 Surya 47 positive positive No No No 8 11 28 Yes 
25 Parvathi 55 positive positive No No No 7 10 24 Yes 
26 Prabha 50 positive positive No Yes No 8 10 26 Yes 
27 Usha rani 46 positive positive No Yes No 9 11 24 Yes 
28 Beula 62 positive positive No Yes Yes 9 9 22 Yes 
29 Poongavanam 35 positive positive Yes No No 9 10 22 Yes 
30 Mumtaz Begam 45 positive positive Yes Yes No 6 11 24 Yes 
  
ABBREVIATIONS 
 
 
 
CAN   – Cardiac autonomic neuropathy 
CAD   – Coronary artery disease 
CHD   – Coronary heart disease 
MI   – Myocardial infarction 
TMT   – Treadmill test 
THR   – Target heart rate 
SHT   – Systemic hypertension 
SBP   – Systolic blood pressure 
DBP   – Diastolic blood pressure 
METS  – Metabolic equivalents 
T2DM  – Type 2 Diabetes mellitus 
BSA   – body surface area 
HR   – Heart rate 
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